Key Points
- Insider Kevin Patrick Danahy sold four separate blocks of 20,000 shares in February (Feb 9, 11, 13 and 17), totaling 80,000 shares and generating about $1.876M in proceeds, reducing his position by 31.6% to 43,298 shares.
- Pulse Biosciences (PLSE) opened at $23.67 and was trading up 2.9%; the stock has a 12‑month range of $12.56–$26.30, a market cap of about $1.6B, a consensus analyst rating of Hold with an average price target near $26, and institutional ownership around 76.95%.
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) insider Kevin Patrick Danahy sold 20,000 shares of the company's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00. Following the completion of the sale, the insider owned 43,298 shares of the company's stock, valued at approximately $1,018,801.94. The trade was a 31.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kevin Patrick Danahy also recently made the following trade(s):
- On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $23.63, for a total transaction of $472,600.00.
- On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total transaction of $429,000.00.
- On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total value of $504,000.00.
Pulse Biosciences Trading Up 2.9%
Shares of PLSE opened at $23.67 on Wednesday. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $26.30. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -20.95 and a beta of 1.77. The stock has a 50 day moving average of $15.75 and a 200 day moving average of $15.90.
Analyst Ratings Changes
A number of research analysts have recently weighed in on PLSE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pulse Biosciences currently has a consensus rating of "Hold" and an average price target of $26.00.
Check Out Our Latest Stock Analysis on Pulse Biosciences
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after acquiring an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after purchasing an additional 619 shares in the last quarter. KLP Kapitalforvaltning AS increased its position in shares of Pulse Biosciences by 136.0% in the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company's stock worth $104,000 after purchasing an additional 3,400 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company's stock valued at $134,000 after purchasing an additional 5,748 shares in the last quarter. Institutional investors own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
